CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. Duell J, Obr A, Augustin M, Endell J, et al. Leuk Lymphoma 2022;63:468-472.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Duell J, Obr A, Augustin M, Endell J, et al. CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. Leuk Lymphoma 2022;63:468-472.
PMID: 34779360